Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DMZL | ISIN: US56400P7069 | Ticker-Symbol: NNFN
Tradegate
21.11.24
08:59 Uhr
6,692 Euro
+0,168
+2,58 %
1-Jahres-Chart
MANNKIND CORPORATION Chart 1 Jahr
5-Tage-Chart
MANNKIND CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
6,5086,70612:38
6,5106,70812:37

Aktuelle News zur MANNKIND Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.11.MannKind Corp: Personalchef Stuart Tross verkauft Aktien im Wert von 403.700 US-Dollar8
08.11.MannKind Corp reports results for the quarter ended in September 30 - Earnings Summary11
07.11.MannKind Corp. Q3 Profit Increases, Beats Estimates245WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) revealed a profit for its third quarter that increased from last year and beat the Street estimates.The company's earnings totaled $11.55 million...
► Artikel lesen
MANNKIND Aktie jetzt für 0€ handeln
07.11.MannKind Non-GAAP EPS of $0.06 beats by $0.03, revenue of $70.08M misses by $4.41M4
07.11.MANNKIND CORP - 8-K, Current Report1
06.11.MannKind Q3 2024 Earnings Preview4
04.11.MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases88Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported with oral nintedanibExpect to meet with the FDA in 1H...
► Artikel lesen
01.11.MannKind (MNKD) Scheduled to Post Earnings on Thursday2
31.10.First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease35ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of...
► Artikel lesen
29.10.MannKind stock soars to 52-week high, touches $6.934
23.10.MannKind Aktie: Kursrückgang trotz positiver Entwicklung255Die MannKind Corporation verzeichnete am 23. Oktober 2024 einen leichten Kursrückgang von 1,75% auf 6,111 EUR. Trotz dieses tagesaktuellen Rückgangs zeigt die Aktie des Biopharma-Unternehmens eine bemerkenswerte...
► Artikel lesen
30.09.MannKind Reports 30-week Results From Phase 4 INHALE-3 Study280WASHINGTON (dpa-AFX) - MannKind (MNKD) reported top-level 30-week results from Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during...
► Artikel lesen
30.09.MannKind: More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)4
21.09.MannKind Corporation (MNKD): Short Seller Sentiment is Bearish4
18.09.MannKind advances phase 3 NTM lung disease study3
18.09.MannKind startet Phase-3-Studie für NTM-Lungenerkrankung10
18.09.MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease124Clearance to proceed also received from health authorities in South Korea and Australia, with Taiwan expected in 4Q 2024First U.S. patient randomized DANBURY, Conn., Sept. 18, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
16.09.MannKind Corporation (MNKD): Short Seller Sentiment is Bearish on This Stock7
14.09.MannKind Aktie: Stabiler Kurs trotz Marktschwankungen
10.09.MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference2
Seite:  Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1